Pharmacogenomics of HIV therapy: Summary of a workshop sponsored by the National Institute of allergy and infectious diseases

HIV Clinical Trials

Volumn 12, Issue 5, 2011, Pages 277-285

  Haas, David ^a   Kuritzkes, Daniel ^b   Ritchie, Marylyn ^a   Amur, Shashi ^c   Gage, Brian ^d   Maartens, Gary ^e   Masys, Dan ^a   Fellay, Jacques ^f   Phillips, Elizabeth ^g   Ribaudo, Heather ^h   Freedberg, Kenneth ⁱ   Petropoulos, Christos ^j   Manolio, Teri ^k   Gulick, Roy ^l   Haubrich, Richard ^m   Kim, Peter ⁿ   Dehlinger, Marjorie ⁿ   Abebe, Rahel ^o   Telenti, Amalio ^f  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g MURDOCH UNIVERSITY   (Australia)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j MONOGRAM BIOSCIENCES   (United States)

^k NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^l WEILL CORNELL MEDICAL COLLEGE   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^o Henry M Jackson Foundation DAIDS   (United States)

more..

Author keywords

HIV therapy; pharmacogenetics; pharmacogenomics; workshop

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; CYTOCHROME P450 2C9; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG TOXICITY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MORTALITY; OVERALL SURVIVAL; PATIENT CARE; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNITED STATES; VIRUS CELL INTERACTION;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (U.S.); PHARMACOGENETICS; UNITED STATES;

EID: 84255190568     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1205-277     Document Type: Article

References (34)

1. UNAIDS Report on the Global AIDS Epidemic. http://www.unaids.org/ globalreport/Global-report.htm. Accessed February 23, 2011.
2. Altman RB, Kroemer HK, McCarty CA, Ratain MJ, Roden D. Pharmacogenomics: will the promise be fulfilled? Nat Rev Genet. 2010;12:69-73.
3. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121-1122. (Pubitemid 34270738)
4. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727-732. (Pubitemid 34215071)
5. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46:1111-1118. (Pubitemid 351589880)
6. Mallal S, Phillips E, Carosi G, et al. HLA-B5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-579. (Pubitemid 351214284)
7. The Panel on Clinical Practices for Treatment of HIV-1. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. January 10, 2011. http://www.aidsinfo.nih.gov/. Accessed February 23, 2011.
8. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400. (Pubitemid 40065906)
9. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15:1-5. (Pubitemid 43205520)
10. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfi navir: an Adult AIDS Clinical Trials Group Study. J Infect Dis. 2005;192:1931-42. (Pubitemid 41681891)
11. Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specifi c CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics. 2006;16:191-198.
12. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther. 2007;81:557-566. (Pubitemid 46454205)
13. Ribaudo HJ, Liu H, Schwab M, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis. 2010;202:717-722.
14. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLADRB10101 and abrogated by low CD4 T-cell counts. AIDS. 2005;19:97-99. (Pubitemid 40111026)
15. Likanonsakul S, Rattanatham T, Feangvad S, et al. HLACw04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res Ther. 2009;6:22-28.
16. Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. HLA-B3505 allele is a strong predictor for nevirapineinduced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics. 2009;19:139-146.
17. Vitezica ZG, Milpied B, Lonjou C, et al. HLA-DRB101 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS. 2008;22:540-541. (Pubitemid 351317299)
18. Lubomirov R, di Iulio J, Fayet A, et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics. 2010;20:217-230.
19. Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are Influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics. 2010;20:112-120.
20. Arab-Alameddine M, Di Iulio J, Buclin T, et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther. 2009;85:485-494.
21. Rotger M, Bayard C, Taffe P, et al. Contribution of genomewide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. Circ Cardiovasc Genet. 2009;2:621-628.
22. Rotger M, Gsponer T, Martinez R, et al. Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals. Clin Infect Dis. 2010;51:1090-1098.
23. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
24. Roden DM, Pulley JM, Basford MA, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 2008;84: 362-369.
25. Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA. 2001;98:12671-12676. (Pubitemid 33020004)
26. O'Mara, et al. Population pharmacodynamic assessment of atazanavir exposure uridine diphosphate-glucuronosyl transferase (UGT) 1A1 genotype and safety in healthy subjects [abstract 3051]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago) Washington DC: American Society for Microbiology 2003.
27. Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis. 2005;192:1381-1386. (Pubitemid 41401151)
28. Kohlrausch FB, de Cassia Estrela R, Barroso PF and Suarez-Kurtz G. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol. 2010;69:95-98.
29. Lillibridge JH, Lee CA and Pithavala YK. The role of polymorphic CYP2C19 in the metabolism of nelfi navir mesylate [abstract 3035]. Presented at XII Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists (San Francisco). Arlington, VA: American Association of Pharmaceutical Scientists; 1998.
30. Saitoh A, Sarles E, Capparelli E, et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS. 2007;21:2191-2199. (Pubitemid 350287217)
31. Chantarangsu S, Cressey TR, Mahasirimongkol S, et al. Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. J Antimicrob Chemother. 2009;64:1265-1273.
32. Mahungu T, Smith C, Turner F, et al. Cytochrome P450 2B6 516G T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med. 2009;10:310-317.
33. Tarr PE, Taffe P, Bleiber G, et al. Modeling the Influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis. 2005;191:1419-1426. (Pubitemid 40563352)
34. Foulkes AS, Wohl DA, Frank I, et al. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med. 2006;3:e52.